Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Therapy For Cervical Dystonia: Review Of The Clinical Evidence And Ongoing Studies

Christoph Kamm, R. Benecke
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Cervical dystonia, also referred to as spasmodic torticollis, is the most frequent form of adult-onset focal dystonia seen in neurological practice. It is characterized by involuntary contractions in a specific set of muscles causing abnormal, sustained and frequently painful postures of the head, neck and shoulders. Intramuscular injection of botulinum toxin (BoNT) into selected muscles is currently considered the treatment of first choice. This has been confirmed by numerous short- and long-term clinical studies, which have established high-quality class I and II evidence (level A recommendation by the American Academy of Neurology) that both BoNT-A and BoNT-B are safe and effective treatment options for cervical dystonia. This review summarizes the clinical evidence currently available and attempts to provide an overview of ongoing clinical studies in this field.
This paper references
10.1136/jnnp.2004.056614
Diffusion tensor imaging in primary cervical dystonia
C. Colosimo (2005)
10.1002/MDS.870030302
Epidemiology of focal and generalized dystonia in Rochester, Minnesota
J. Nutt (1988)
10.1002/ANA.410420117
Sporadic focal dystonia in Northwest Germany: Molecular basis on chromosome 18p
B. Leube (1997)
10.1002/mds.21295
Structural white matter abnormalities in patients with idiopathic dystonia
L. Bonilha (2007)
10.1002/mds.22406
Reverse sensory geste in cervical dystonia
F. Asmus (2009)
10.1002/mds.23137
The diagnostic challenge of primary dystonia: Evidence from misdiagnosis
S. Lalli (2010)
10.1111/j.1468-1331.2010.03042.x
EFNS guidelines on diagnosis and treatment of primary dystonias
Alberto Albanese (2011)
10.1136/jnnp.72.4.430
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
W. Poewe (2002)
Strong genetic evidence for association of DYT1 with idiopathic dystonia
C Kamm (2006)
10.1212/01.wnl.0000183055.81056.5c
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia
C. Comella (2005)
10.1002/mds.22157
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
M. Brin (2008)
10.1212/01.wnl.0000249308.66959.43
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
J. Jankovic (2006)
10.1002/MDS.870080411
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
P. E. Greene (1993)
[Pharmacological aspects of therapeutic botulinum toxin preparations].
D. Dressler (2006)
10.1002/mds.20403
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study
D. Truong (2005)
10.1136/jnnp.64.1.6
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
T. Odergren (1998)
10.1212/WNL.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
A. Brashear (1999)
10.1111/j.1468-1331.2007.02034.x
Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm
G. Fabbrini (2008)
10.1002/mds.20290
Long‐term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia
B. Berman (2005)
10.1002/mds.21724
Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial
E. Pappert (2008)
10.1093/BRAIN/AWM229
The Canadian multicentre study of deep brain stimulation for cervical dystonia.
Z. Kiss (2007)
10.1002/MDS.870060210
Treatment of idiopathic spasmodic torticollis with botulinum toxin a: A double‐blind study on twenty‐three patients
I. Lorentz (1991)
10.1002/ana.20485
Torsin A haplotype predisposes to idiopathic dystonia
J. Clarimon (2005)
10.1002/MDS.870090216
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
A pilot study on the use of botulinum toxin in spasmodic torticollis. Can
J K Tsui (1985)
Botox) in healthy volunteers
T Odergren (2005)
10.1212/wnl.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
M. Brin (1999)
10.1001/ARCHNEUR.1990.00530050070014
Natural history of adult-onset idiopathic torticollis.
M. Jahanshahi (1990)
10.1159/000116969
Genetic contribution to idiopathic adult-onset blepharospasm and cranial-cervical dystonia.
G. Defazio (1993)
10.1212/01.wnl.0000252932.71306.89
Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia
S. W. Hung (2007)
10.1212/WNL.49.3.701
Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia
M. Lew (1997)
10.1016/j.parkreldis.2010.03.002
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
D. Truong (2010)
10.1016/J.CLINTHERA.2007.07.020
Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
M. A. Chapman (2007)
Concept and classification of dystonia.
S. Fahn (1988)
10.1016/0090-3019(93)90118-K
Selective peripheral denervation for spasmodic torticollis: surgical technique, results, and observations in 260 cases.
C. Bertrand (1993)
10.1002/mds.23225
Genetic evidence for an association of the TOR1A locus with segmental/focal dystonia
N. Sharma (2010)
10.1097/00002826-199008000-00011
Failure of fixed-dose, fixed muscle injection of botulinum toxin in torticollis.
W. Koller (1990)
Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study
D Truong (2005)
Safety and efficacy of repeated NT 201 ( botulinum neurotoxin type A free from complexing proteins ) injections of patients with cervical dystonia : a first long - term safety analysis
A Hanschmann
10.1212/WNL.42.4.878
Botulinum toxin injection for spasmodic torticollis
C. Comella (1992)
10.1016/0005-2795(70)90011-5
Purification of Clostridium botulinum type A toxin.
B. Dasgupta (1970)
10.1111/j.1468-1331.2010.03130.x
Botulinum toxin assessment, intervention and aftercare for cervical dystonia and other causes of hypertonia of the neck: international consensus statement
I. Novak (2010)
10.1002/mds.23254
Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications
M. Naumann (2010)
Classification of dystonia.
S. Fahn (1998)
10.1136/jnnp.52.1.57
Vestibulo-ocular abnormalities in spasmodic torticollis before and after botulinum toxin injections.
R. Stell (1989)
10.1136/bmj.297.6648.616
Botulinum toxin treatment of spasmodic torticollis.
R. Stell (1988)
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
K. Kessler (1999)
10.1212/01.wnl.0000311389.26145.95
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review)
D. Simpson (2008)
10.1212/WNL.46.4.1066
Botulinum toxin versus trihexyphenidyl in cervical dystonia
J. Brans (1996)
Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
D. Dressler (2005)
10.1136/jnnp.72.4.459
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
D. Ranoux (2002)
The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group A prevalence study of primary dystonia in eight European countries
T. Warner (2000)
10.1007/BF00839206
Treatment of spasmodic torticollis with local injections of botulinum toxin
W. Poewe (2004)
10.1038/nrn2337
The pathophysiological basis of dystonias
X. Breakefield (2008)
10.1007/s00415-003-1129-6
Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure
D. Dressler (2003)
10.1016/S0140-6736(86)92070-2
DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS
J. C. Tsui (1986)
10.1007/s00702-004-0234-8
Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteers
W. Jost (2004)
10.1007/s00115-006-2090-2
Pharmakologische Aspekte therapeutischer Botulinum-Toxin-Präparationen
D. Dressler (2006)
10.1046/J.1524-4725.2002.29083.X
Botulinum Toxin Type B
N. Sadick (2003)
10.1212/01.wnl.0000267425.51598.c9
Minimum incidence of primary cervical dystonia in a multiethnic health care population
C. Marras (2007)
10.1212/01.WNL.0000026474.12594.0D
The prevalence of primary dystonia in the general community
J. Müller (2002)
10.1007/BF00867421
A genetic study of idiopathic focal dystonias
M. Stojanovic (2004)
10.1007/s004150050345
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency
K. Kessler (1999)
10.1007/s00702-010-0529-x
Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm
B. Wabbels (2010)
10.1017/S031716710003540X
A pilot study on the use of botulinum toxin in spasmodic torticollis.
J. Tsui (1985)
10.1097/NRL.0b013e31816f2cdd
Clinical Comparisons of Botulinum Neurotoxin Formulations
A. Brashear (2008)
10.1007/s004150070094
A prevalence study of primary dystonia in eight European countries
T. Warner (2000)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
10.1111/j.1468-1331.2010.03045.x
Craniocervical dystonia: clinical and pathophysiological features
C. Colosimo (2010)
10.1002/ANA.410290407
Change in pattern of muscle activity following botulinum toxin injections for torticollis
D. Gelb (1991)
10.1212/WNL.40.8.1213
Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis
P. Greene (1990)
10.1212/WNL.40.2.277
Botulinum toxin injections for cervical dystonia
J. Jankovic (1990)
10.1002/mds.20531
Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia
S. Factor (2005)
10.1212/WNL.50.5_SUPPL_5.S1
Tolcapone: COMT inhibition for the treatment of Parkinson's disease.
S. Fahn (1998)
10.1212/WNL.0b013e31820f2e4f
Subthalamic nucleus deep brain stimulation in primary cervical dystonia
J. Ostrem (2011)
10.1002/mds.20468
Retrospective evaluation of the dose of dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study
A. Marchetti (2005)
10.1212/01.wnl.0000174433.76707.8c
Autonomic function after botulinum toxin type A or B: A double-blind, randomized trial
R. Tintner (2005)
10.1212/WNL.39.1.80
Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis
D. Gelb (1989)
10.1159/000067023
Autonomic Side Effects of Botulinum Toxin Type B Treatment of Cervical Dystonia and Hyperhidrosis
D. Dressler (2002)
10.1212/WNL.43.9.1715
Botulinum antibodies in dystonic patients treated with type A botulinum toxin
M. Zuber (1993)
10.1212/01.wnl.0000244423.63406.17
Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia
C. Kamm (2006)
10.1007/s004150170028
Efficacy and safety of a standardised 500 unit dose of Dysport® (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study
J. Wissel (2001)
10.1136/jnnp.64.1.13
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®
W. Poewe (1998)
10.1007/PL00007848
A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia
M. Naumann (2002)
10.1212/01.WNL.0000163767.99354.C3
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R. Benecke (2005)
10.1093/BRAIN/AWL355
Do primary adult-onset focal dystonias share aetiological factors?
G. Defazio (2007)
10.1111/j.1468-1331.2009.02878.x
Xeomin® in the treatment of cervical dystonia
R. Benecke (2009)
10.1212/01.wnl.0000203344.43342.18
Lack of association with TorsinA haplotype in German patients with sporadic dystonia
S. Hague (2006)
10.1016/S1474-4422(04)00907-X
Epidemiology of primary dystonia
G. Defazio (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar